Sandoz launched biosimilar Filgrastim BS Injection syringes in Japan

December 8, 2014 7:56 AM

Sandoz, the generic pharmaceutical division of Novartis, last week announced the launch in Japan of biosimilar Filgrastim BS Injection 75 µg/150 µg/300 µg Syringe. Filgrastim is used with certain cancer patients to accelerate recovery of infection-fighting white blood cells after chemotherapy (prevention of neutropenia) and is also used to stimulate mobilization of hematopoietic stem cells for collection and transplantation.

“As the pioneer and global leader in biosimilars we are very pleased to announce the launch of our second biosimilar product in Japan”, said Junichi Nakamichi, Country Head of Sandoz Japan. “Sandoz’s filgrastim is marketed in over 50 countries. We are pleased to make this important product available to patients and healthcare professionals in Japan.”

Sandoz Japan will co-promote the product with Sawai Pharmaceutical Co., Ltd.

 

Source: Sandoz

Comments are closed

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!